文献速递胰腺与胆道疾病消化道出血消化内镜

临床显著的内镜逆行胰胆管造影术后出血的发生率、预测因素和结局:一项当代多中心研究

Incidence, Predictors, and Outcomes of Clinically Significant Post-Endoscopic Retrograde Cholangiopancreatography Bleeding: A Contemporary Multicenter Study.
PubMed 文献 · Am J Gastroenterol · 2024-07-05

该多中心前瞻性研究分析了2018至2024年间8517例内镜逆行胰胆管造影术(ERCP),临床显著的ERCP术后出血(CSPEB)发生率为1.5%(129例),平均发生于术后3.2天。高风险干预后CSPEB发生率为2.3%(110/4849),P2Y12抑制剂、华法林、达比加群、利伐沙班和阿哌沙班均与CSPEB相关。CSPEB患者中86.0%需内镜检查、53.5%需输血,2.3%死亡。

要点

  • CSPEB总体发生率为1.5%,高风险干预后为2.3%,平均发生于术后3.2天。
  • 高风险ERCP后,P2Y12抑制剂、华法林、达比加群、利伐沙班和阿哌沙班均与CSPEB相关。
  • CSPEB后30天内伴随心肺事件更频繁(OR 12.71)。

核心结论

  • 内镜医师可能基于高风险ERCP前抗血小板药物停用不充分的观察而低估抗血小板相关CSPEB的风险。
  • 适当的围手术期抗血栓管理至关重要,可能成为新的质量改进目标。

研究设计与样本

  • 多中心前瞻性ERCP数据分析,纳入2018年至2024年间病例,随访30天。
  • 共分析8517例ERCP,使用Firth逻辑回归,P值<0.05为显著,报告比值比(OR)和95%置信区间。

主要发现

  • CSPEB发生于129/8517例ERCP(1.5%),平均发生时间为3.2天。
  • 高风险干预(括约肌切开术、括约肌成形术、预切开括约肌切开术和/或针刀开窗术)后CSPEB发生110/4849例(2.3%)。
  • CSPEB患者中86.0%需内镜检查,53.5%需输血,3例(2.3%)死亡。
  • 高风险干预后,P2Y12抑制剂(OR 3.33,95%CI 1.26-7.74)、华法林(OR 8.54,95%CI 3.32-19.81)、达比加群(OR 13.40,95%CI 2.06-59.96)、利伐沙班(OR 7.42,95%CI 3.43-15.24)和阿哌沙班(OR 4.16,95%CI 1.99-8.20)与CSPEB相关。
  • 括约肌切开术后显著术中出血与CSPEB相关(OR 2.32,95%CI 1.06-4.60),括约肌成形术后则无此关联。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Clinically significant post-endoscopic retrograde cholangiopancreatography (ERCP) bleeding (CSPEB) is common. Contemporary estimates of risk are lacking. We aimed to identify risk factors of and outcomes after CSPEB. METHODS: We analyzed multicenter prospective ERCP data between 2018 and 2024 with 30-day follow-up. The primary outcome was CSPEB, defined as hematemesis, melena, or hematochezia resulting in (i) hemoglobin drop ≥ 20 g/L or transfusion and/or (ii) endoscopy to evaluate suspected bleeding and/or (iii) unplanned healthcare visitation and/or prolongation of existing admission. Firth logistic regression was used. P values <0.05 were significant, with odds ratios (ORs) and 95% confidence intervals reported. RESULTS: CSPEB occurred after 129 (1.5%) of 8,517 ERCPs (mean onset 3.2 days), with 110 of 4,849 events (2.3%) occurring after higher risk interventions (sphincterotomy, sphincteroplasty, precut sphincterotomy, and/or needle-knife access). Patients with CSPEB required endoscopy and transfusion in 86.0% and 53.5% of cases, respectively, with 3 cases (2.3%) being fatal. P2Y 12 inhibitors were held for a median of 4 days (interquartile range 4) before higher risk ERCP. After higher risk interventions, P2Y 12 inhibitors (OR 3.33, 1.26-7.74), warfarin (OR 8.54, 3.32-19.81), dabigatran (OR 13.40, 2.06-59.96), rivaroxaban (OR 7.42, 3.43-15.24), and apixaban (OR 4.16, 1.99-8.20) were associated with CSPEB. Significant intraprocedural bleeding after sphincterotomy (OR 2.32, 1.06-4.60), but not after sphincteroplasty, was also associated. Concomitant cardiorespiratory events occurred more frequently within 30 days after CSPEB (OR 12.71, 4.75-32.54). DISCUSSION: Risks of antiplatelet-related CSPEB may be underestimated by endoscopists based on observations of suboptimal holding before higher risk ERCP. Appropriate periprocedural antithrombotic management is essential and could represent novel quality initiative targets.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Bishay K, Ruan Y, Barkun AN, et al. Incidence, Predictors, and Outcomes of Clinically Significant Post-Endoscopic Retrograde Cholangiopancreatography Bleeding: A Contemporary Multicenter Study. Am J Gastroenterol. 2024. PMID: 39495582. doi:10.14309/ajg.0000000000002946

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。